TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-12-14
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
875
Registration Number
NCT02629861
Locations
🇺🇸

Teva Investigational Site 13536, Springfield, Missouri, United States

🇺🇸

Teva Investigational Site 13609, Akron, Ohio, United States

🇺🇸

Teva Investigational Site 13634, Akron, Ohio, United States

and more 137 locations

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-12-04
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1130
Registration Number
NCT02621931
Locations
🇺🇸

Teva Investigational Site 13585, Chicago, Illinois, United States

🇺🇸

Teva Investigational Site 13626, Columbus, Ohio, United States

🇺🇸

Teva Investigational Site 13568, Encino, California, United States

and more 136 locations

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

First Posted Date
2015-07-31
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
713
Registration Number
NCT02513160
Locations
🇺🇸

Teva Investigational Site 13391, Pittsburgh, Pennsylvania, United States

🇺🇸

Teva Investigational Site 13420, San Diego, California, United States

🇺🇸

Teva Investigational Site 13416, Miami, Florida, United States

and more 72 locations

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

First Posted Date
2015-07-17
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
177
Registration Number
NCT02501629
Locations
🇺🇸

Teva Investigational Site 13349, Cincinnati, Ohio, United States

🇺🇸

Teva Investigational Site 13357, Bakersfield, California, United States

🇺🇸

Teva Investigational Site 13365, Long Beach, California, United States

and more 124 locations

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-07-16
Last Posted Date
2021-12-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
861
Registration Number
NCT02499900
Locations
🇺🇸

Teva Investigational Site 13483, Golden Valley, Minnesota, United States

🇧🇪

Teva Investigational Site 37063, Edegem, Belgium

🇦🇷

Teva Investigational Site 20062, Buenos Aires, Argentina

and more 94 locations

Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-07-01
Last Posted Date
2022-03-31
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
569
Registration Number
NCT02487108
Locations
🇺🇸

Teva Investigational Site 13173, Anaheim, California, United States

🇺🇸

Teva Investigational Site 13510, Phoenix, Arizona, United States

🇺🇸

Teva Investigational Site 13174, Bakersfield, California, United States

and more 5 locations

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-05-22
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
468
Registration Number
NCT02452190
Locations
🇺🇸

Teva Investigational Site 13215, Bakersfield, California, United States

🇺🇸

Teva Investigational Site 13235, Shiloh, Illinois, United States

🇺🇸

Teva Investigational Site 13208, Tallahassee, Florida, United States

and more 223 locations

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-05-07
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
43
Registration Number
NCT02437604
Locations
🇺🇸

Teva Investigational Site 13178, Raleigh, North Carolina, United States

🇺🇸

Teva Investigational Site 13179, San Antonio, Texas, United States

🇺🇸

Teva Investigational Site 13177, Edmond, Oklahoma, United States

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2015-04-07
Last Posted Date
2021-12-10
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
34
Registration Number
NCT02410356
Locations
🇺🇸

Teva Investigational Site 13166, Fountain Valley, California, United States

🇺🇸

Teva Investigational Site 13142, Pittsburgh, Pennsylvania, United States

🇺🇸

Teva Investigational Site 13144, Arlington, Texas, United States

and more 47 locations

Study of TV-1106 in Growth Hormone-Deficient Adults

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2015-04-07
Last Posted Date
2022-01-24
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
14
Registration Number
NCT02410343
Locations
🇬🇷

Teva Investigational Site 63054, Athens, Greece

🇷🇺

Teva Investigational Site 50303, Saint-Petersburg, Russian Federation

🇺🇸

Teva Investigational Site 13112, Henderson, Nevada, United States

and more 30 locations
© Copyright 2024. All Rights Reserved by MedPath